Neovasc Inc (NVCN)

[maz1978]

Cliff note DD packet for those new to NVCN showing why so many have turned bullish

A SMALL CLIP ON TIARA



NOW LOOK AT WHO WAS BROUGHT INTO AS PRESIDENT AND THE CONNECTIONS WITH BOSTON SCIENTIFIC!!!

Neovasc Inc. (Nasdaq: NVCN), a front-runner in minimally invasive transcatheter mitral valve technologies today announced that its board of directors (the "Board") has appointed Fred A. Colen as president and chief executive officer effective immediately. This leadership transition is a key element of the Company's strategy to support plans for the commercialization of its new-to-market Reducer™ ("Reducer") product in Europe and the advancement of its Tiara™ ("Tiara") mitral valve clinical program. Alexei Marko, Neovasc's outgoing CEO, will maintain his role as a Director on the Neovasc Board of Directors and continue to serve as an advisor to the Company.

"After ten years building Neovasc, I am convinced that now is the time for new leadership to take the Company to the next level. I am especially pleased that an industry leader of Fred Colen's caliber has accepted this opportunity," said Alexei Marko, outgoing CEO of Neovasc. "I look forward to my continued involvement as a board member."

Fred Colen has contributed to many significant turnarounds in his career, including the post-acquisition Guidant Company, which became the CRM division of Boston Scientific, a firm with which he held progressively senior executive roles over 11 years[/b], including Chief Technology Officer from 2001-2008 and Member of the Executive Committee from 2001-2010. During his tenure at Boston Scientific, Mr. Colen is credited with numerous successes. As President of the company's Cardiac Rhythm Management (CRM) Group his team regained trust and confidence in the division's implantable pacemakers, leads, defibrillators and re-synchronization devices, increasing annual product revenue growth by over 10% in a flat US market and growing global divisional operating income from below 10% to 25% of sales, exceeding the planned annual free cash flow goals. As Chief Technology Officer, he led the development and global commercial launch for the Company's first- and second-generation implantable drug-eluting coronary stents (the Taxus Express and Taxus Liberte), leading to global market leadership with incremental revenues of US$2 billion annually. The Taxus Express market introduction is viewed as one of the most successful launches ever in the medical device industry.

NOW START CONNECTING THE DOTS:



https://www.prnewswire.com/news-releases/neovasc-and-boston-scientific-close-us75-million-agreement-606242846.html







THESE HOLDINGS HAVE INCREASED SINCE





INSIDERS CURRENTLY OWN OVER 30% AS WELL!!!



NOW LOOK AT WHAT EXPERT ANALYST ARE CLAIMING





ALL GOES HAND IN HAND WITH THE RECORD VOLUME THIS IS NOW SEEING AT .019 AND THE SUBSTANTIAL BUYING PRESSURE WE ARE SEEING







THERE HAVE BEEN MANY 500K, 350K, AND 250K BUYS AS WELL...I JUST WASN'T QUICK ENOUGH TO GET THE SCREENSHOTS...